Literature DB >> 25702072

Assessment of completion of early medical abortion using a text questionnaire on mobile phones compared to a self-administered paper questionnaire among women attending four clinics, Cape Town, South Africa.

Deborah Constant1, Katherine de Tolly2, Jane Harries3, Landon Myer4.   

Abstract

In-clinic follow-up to assess completion of medical abortion is no longer a requirement according to World Health Organization guidance, provided adequate counselling is given. However, timely recognition of ongoing pregnancy, complications or incomplete abortion, which require treatment, is important. As part of a larger trial, this study aimed to establish whether women having a medical abortion could self-assess whether their abortion was complete using an automated, interactive questionnaire on their mobile phones. All 469 participants received standard abortion care and all returnees filled in a self-assessment on paper at clinic follow-up 2-3 weeks later. The 234 women allocated to receive the phone messages were also asked to do a mobile phone assessment at home ten days post-misoprostol. Completion of the mobile assessment was tracked by computer and all completed assessments, paper and mobile, were compared to providers' assessments at clinic follow-up. Of the 226 women able to access the mobile phone assessment, 176 (78%) completed it; 161 of them (93%) reported it was easy to do so. Neither mobile nor paper self-assessments predicted all cases needing additional treatment at follow-up. Prediction of complete procedures was good; 71% of mobile assessments and 91% of paper assessments were accurate. We conclude that an interactive questionnaire assessing completion of medical abortion on mobile phones is feasible in the South African setting; however, it should be done later than day 10 and combined with an appropriate pregnancy test to accurately detect incomplete procedures.
Copyright © 2015 Reproductive Health Matters. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  South Africa; follow-up; medical abortion; mobile phones; self-assessment of complete abortion; text messaging

Mesh:

Substances:

Year:  2015        PMID: 25702072     DOI: 10.1016/S0968-8080(14)43791-1

Source DB:  PubMed          Journal:  Reprod Health Matters        ISSN: 0968-8080


  6 in total

1.  Is self-assessment of medical abortion using a low-sensitivity pregnancy test combined with a checklist and phone text messages feasible in South African primary healthcare settings? A randomized trial.

Authors:  Deborah Constant; Jane Harries; Kristen Daskilewicz; Landon Myer; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

Review 2.  A research agenda for moving early medical pregnancy termination over the counter.

Authors:  N Kapp; D Grossman; E Jackson; L Castleman; D Brahmi
Journal:  BJOG       Date:  2017-04-27       Impact factor: 6.531

3.  Telemedicine for medical abortion: a systematic review.

Authors:  M Endler; A Lavelanet; A Cleeve; B Ganatra; R Gomperts; K Gemzell-Danielsson
Journal:  BJOG       Date:  2019-04-25       Impact factor: 6.531

Review 4.  Exploring the ambivalent evidence base of mobile health (mHealth): A systematic literature review on the use of mobile phones for the improvement of community health in Africa.

Authors:  Eva Fm Krah; Johannes G de Kruijf
Journal:  Digit Health       Date:  2016-11-24

5.  The EQ-5D-3L administered by text message compared to the paper version for hard-to-reach populations in a rural South African trauma setting: a measurement equivalence study.

Authors:  Henry G Burnand; Samuel E McMahon; Adrian Sayers; Tembisa Tshengu; Norrie Gibson; Ashley W Blom; Michael R Whitehouse; Vikki Wylde
Journal:  Arch Orthop Trauma Surg       Date:  2020-08-12       Impact factor: 3.067

6.  Legal and policy responses to the delivery of abortion care during COVID-19.

Authors:  Elizabeth Chloe Romanis; Jordan A Parsons
Journal:  Int J Gynaecol Obstet       Date:  2020-10-05       Impact factor: 4.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.